Sanyal, A., Ling, L., Neff, G., Guy, C., Bashir, M., Paredes, A., … Harrison, S. (2021). Aldafermin reduces hydrophobic bile acids in a 24-week, randomized, double-blind, placebo-controlled, multicenter study in patients with non-alcoholic steatohepatitis. In JOURNAL OF HEPATOLOGY (Vol. 75, pp. S616–S617).

Sanyal, Arun, Lei Ling, Guy Neff, Cynthia Guy, Mustafa Bashir, Angelo Paredes, Juan Frias, et al. “Aldafermin reduces hydrophobic bile acids in a 24-week, randomized, double-blind, placebo-controlled, multicenter study in patients with non-alcoholic steatohepatitis.” In JOURNAL OF HEPATOLOGY, 75:S616–17, 2021.

Sanyal A, Ling L, Neff G, Guy C, Bashir M, Paredes A, et al. Aldafermin reduces hydrophobic bile acids in a 24-week, randomized, double-blind, placebo-controlled, multicenter study in patients with non-alcoholic steatohepatitis. In: JOURNAL OF HEPATOLOGY. 2021. p. S616–7.

Sanyal, Arun, et al. “Aldafermin reduces hydrophobic bile acids in a 24-week, randomized, double-blind, placebo-controlled, multicenter study in patients with non-alcoholic steatohepatitis.” JOURNAL OF HEPATOLOGY, vol. 75, 2021, pp. S616–17.

Sanyal A, Ling L, Neff G, Guy C, Bashir M, Paredes A, Frias J, Younes ZH, Trotter JF, Gunn NT, Moussa S, Kohli A, Nelson K, Gottwald M, Chang W, Yan A, DePaoli A, Lieu H, Harrison S. Aldafermin reduces hydrophobic bile acids in a 24-week, randomized, double-blind, placebo-controlled, multicenter study in patients with non-alcoholic steatohepatitis. JOURNAL OF HEPATOLOGY. 2021. p. S616–S617.